Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 1.00 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 1.00 |
| ▸ | BCKDK | O14874 | 2/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | RPA1 | P27694 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11398368 | 0.98 | MCL1 (0.97) | MCL1BCL2L1BCKDKRXFP1NPC1 | |
| SCHEMBL17173224 | 0.88 | MCL1 (0.79) | MCL1BCL2L1BCKDKRXFP1NPC1 | |
| SCHEMBL415459 | 0.87 | MCL1 (0.77) | MCL1BCL2L1BCKDKRXFP1NPC1 | |
| SCHEMBL5023231 | 0.87 | MCL1 (0.77) | MCL1BCL2L1BCKDKRXFP1NPC1 | |
| SCHEMBL9178739 | 0.85 | MCL1 (0.74) | MCL1BCL2L1BCKDKRXFP1NPC1 | |
| SCHEMBL26267893 | 0.83 | MCL1 (0.71) | MCL1BCL2L1BCKDKRXFP1NPC1 | |
| SCHEMBL15619574 | 0.83 | MCL1 (0.71) | MCL1BCL2L1BCKDKRXFP1NPC1 | |
| SCHEMBL6886010 | 0.83 | MCL1 (1.00) | MCL1BCL2L1BCKDKRXFP1NPC1 | |
| SCHEMBL13819863 | 0.83 | MCL1 (0.70) | MCL1BCL2L1BCKDKRXFP1NPC1 | |
| SCHEMBL13659630 | 0.83 | MCL1 (0.70) | MCL1BCL2L1BCKDKRXFP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114409663-B | Zinc phthalocyanine 3-chloro-6 methylbenzo [ b ] thiophene-2-carboxylic acid conjugates targeting Mcl-1 enzyme and methods of making the same | 福州大学 | 2023-05-30 | — | — | CN | claimed |
| CN-114409663-A | Mcl-1 enzyme targeted zinc phthalocyanine 3-chloro-6 methylbenzo [ b ] thiophene-2-carboxylic acid conjugates and methods of making the same | 福州大学 | 2022-04-29 | — | — | CN | claimed |
| US-8431684-B2 | Process for the preparation of ibodutant (MEN15596) and related intermediates | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2013-04-30 | — | — | US | claimed |
| EP-2432778-B1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI SAS (IT) | 2013-03-20 | — | — | EP | claimed |
| EP-2432778-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | Malesci Istituto Farmacobiologico S.p.a. (IT) | 2012-03-28 | — | — | EP | claimed |
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2012-03-15 | — | — | US | claimed |
| WO-2010133306-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2010-11-25 | — | — | WO | claimed |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-11-13 | — | — | US | disclosed |
| EP-4431505-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2024-09-18 | — | — | EP | disclosed |
| CN-118234721-A | Isoindolinone derivative with glutarimide mother nucleus and application thereof | 韩国化学研究院 | 2024-06-21 | — | — | CN | disclosed |
| CN-114409663-B | Zinc phthalocyanine 3-chloro-6 methylbenzo [ b ] thiophene-2-carboxylic acid conjugates targeting Mcl-1 enzyme and methods of making the same | 福州大学 | 2023-05-30 | — | — | CN | disclosed |
| CN-114409663-B | Zinc phthalocyanine 3-chloro-6 methylbenzo [ b ] thiophene-2-carboxylic acid conjugates targeting Mcl-1 enzyme and methods of making the same | 福州大学 | 2023-05-30 | — | — | CN | disclosed |
| CN-114409663-B | Zinc phthalocyanine 3-chloro-6 methylbenzo [ b ] thiophene-2-carboxylic acid conjugates targeting Mcl-1 enzyme and methods of making the same | 福州大学 | 2023-05-30 | — | — | CN | disclosed |
| EP-1797065-A4 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1891951-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2008-02-27 | — | — | EP | disclosed |
| EP-1414797-B1 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYLIC STRUCTURE | BOEHRINGER INGELHEIM CA LTD (CA) | 2008-01-02 | — | — | EP | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| EP-1797065-A2 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007016784-A1 | NOVEL SUBSTITUTED 1,2,3-TΠAZOLYLMETHYL-BENZOTHIOPHENE OR -INDOLE AND THEIR USE AS LEUKOTΠENE BIOSYNTHESIS INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006029210-A2 | ACYCLIC 1,3-DIAMINES AND USES THEREFOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065370-A1 | PROCESS FOR THE PREPARATION OF IBODUTANT (MEN15596) AND RELATED INTERMEDIATES | DDT, BBOX1, IMPDH2 | MCL1 2699/4885BCL2L1 4430/4885BCKDK 736/4885 |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | MCL1 4289/4885BCL2L1 2013/4885BCKDK 1865/4885 |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | CRBN, IDH1, IDH2 | MCL1 121/4885BCL2L1 842/4885BCKDK 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.